Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Down Syndrome peptide trials
2 selected ClinicalTrials.gov records carrying the official condition label Down Syndrome. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
2 selected records.
2 profiles.
2021–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 56 selected PubMed records and 14 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Down Syndrome unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT04751136
PeptideScanner retained ClinicalTrials.gov record NCT04751136 at 2026-11-16T17:33:14.861Z. Its registry update date was 2021-02-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 11, 2021
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT04278404
PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- August 21, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Bivalirudin · 2026-08-21
ClinicalTrials.gov record NCT04278404
Recruiting at the retained observation.
Open attributed record →Cerebrolysin · 2021-02-11
ClinicalTrials.gov record NCT04751136
Completed at the retained observation.
Open attributed record →